LOGIN  |  REGISTER
Amneal Pharmaceuticals
Compass Therapeutics

Quest Diagnostics Releases 2023 Corporate Responsibility Report

June 27, 2024 | Last Trade: US$163.59 0.30 -0.18

SECAUCUS, N.J., June 27, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today released its 2023 Corporate Responsibility Report.

Quest Diagnostics Releases 2023 Corporate Responsibility Report

This year's report provides information on the company's corporate responsibility strategy and environmental, social, and governance (ESG) priorities, which align with The Quest Way, the company's approach to achieving its goals. The Quest Way is comprised of the company's Purpose, strategy and culture.

"The theme of this year's report, Care at Our Core, builds on our Purpose of working together to create a healthier world, one life at time," said Jim Davis, Chairman, CEO and President.

"The Quest Way guides our corporate responsibility strategy and progress toward our environmental, social, and governance priorities and goals. This report shares some of our contributions from 2023 and demonstrates how we are continuing to improve our processes and capabilities surrounding this work. I am proud of our critical role in healthcare and how our workforce is the engine that expands access and advances innovative contributions."

The report details the initiatives supporting the company's four corporate responsibility strategic pillars:

  • Employee and community engagement
  • Equity and health access
  • Governance and ethics
  • Environmental sustainability

The report features key impact areas and highlights from 2023, including: 

  • More than $16 million in corporate giving to communities nationwide.
  • Approximately 950,000 donated or discounted test requisitions through the company's patient assistance programs and Quest for Health Equity, the company's initiative with the Quest Diagnostics Foundation to reduce health disparities in under-resourced and marginalized communities.
  • With 70 active programs, the Quest for Health Equity initiative has supported communities in 30 states, Washington, D.C. and Puerto Rico since its inception in 2020.
  • Employees volunteered more than 30,000 hours to support local communities and causes.
  • Launched the HealthyQuest Employee Business Network (EBN) to offer programs and community support to promote employees' well-being. The company now has 11 EBNs with ~8,000 members.
  • Successfully eliminated shipped medical waste from two of our California laboratories by installing on-site treatment technology.
  • Additionally, the company received ISO 14001 environmental management certification for its laboratories in Cleveland, OH, and Chantilly, VA.

"In 2023, we made good progress across all of our pillars, especially in the areas of employee and community engagement," said Sam Samad, Executive Vice President and Chief Financial Officer, who leads the team guiding the company's ESG efforts. "Our efforts to create a healthier world require collaboration with our employees, customers, partners and communities where we operate, and those efforts are driving tangible results."

Click here to view the report on the Quest Diagnostics corporate website.

About Quest Diagnostics

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB